论文部分内容阅读
目的探讨阿拓莫兰治疗酒精性肝病的保肝、降酶、退黄等的临床疗效。方法 80例酒精性肝病患者随机分为阿拓莫兰治疗组42例(阿拓莫兰注射液1800 mg/d+甘利欣、维生素C、复方氨基酸注射液静脉滴注),对照组38例(甘利欣、维生素C、复方氨基酸注射液静脉滴注),疗程30 d,分别观察两组治疗30 d后丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、谷氨酰转肽酶(GGT)、总胆红素(TBiL)、总胆汁酸(TBA)等肝功能指标恢复情况及症状改善情况。结果治疗组治疗后ALT、AST、TBiL、GGT、TBA值较治疗前明显下降(P<0.05),其下降幅度大于对照组。结论阿拓莫兰治疗酒精性肝病疗效明确,无不良反应,安全性良好。
Objective To investigate the clinical efficacy of Addon Moran in the treatment of alcoholic liver disease, such as liver protection, enzyme lowering and yellowing. Methods Eighty patients with alcoholic liver disease were randomly divided into three groups: 42 cases in the treatment group (methotretinoin 1800 mg / d + Glycyrrhizin, vitamin C, compound amino acid injection intravenous drip) and 38 cases in the control group Yan, vitamin C, compound amino acid injection intravenous drip) for 30 days. The levels of ALT, AST, glutamyl (GGT), total bilirubin (TBiL), total bile acid (TBA) and other indicators of liver function recovery and improvement of symptoms. Results After treatment, the levels of ALT, AST, TBiL, GGT and TBA in treatment group decreased significantly (P <0.05) compared with those before treatment, and the decrease extent was greater than that in control group. Conclusion Addon Moran treatment of alcoholic liver disease clear effect, no adverse reactions, good safety.